Hims & Hers to Acquire Eucalyptus for Up to $1.15B, Accelerating Global Digital Health Expansion

summarizeSummary

Hims & Hers Health, Inc. announced a definitive agreement to acquire Eucalyptus, an international digital health leader, for up to $1.15 billion, significantly expanding its global footprint and aiming for category leadership in key international markets.

check_boxKey Events

• Major Acquisition Announced

  Hims & Hers Health, Inc. has entered into a definitive agreement to acquire Eucalyptus, an international digital health company, for an aggregate consideration of up to approximately $1.15 billion.

• Strategic International Expansion

  The acquisition is expected to accelerate Hims & Hers' global expansion, deepening its presence in the UK, Germany, and Canada, and entering new markets including Australia and Japan.

• Payment Structure Details

  The consideration includes approximately $240 million in upfront cash, $710 million in deferred payments over 18 months, and up to $200 million in earnout payments tied to revenue and adjusted EBITDA targets through early 2029. Hims & Hers has the option to settle the majority of deferred and earnout payments in cash or stock.

• Eucalyptus Financial Performance

  Eucalyptus currently has an annual revenue run-rate (ARR) north of $450 million USD, with triple-digit year-over-year ARR growth in each quarter of calendar year 2025.

auto_awesomeAnalysis

Hims & Hers Health, Inc. announced a definitive agreement to acquire Eucalyptus, an Australia-based digital health company, for up to $1.15 billion. This is a highly significant strategic move, representing over 30% of Hims & Hers' current market capitalization, and comes as the company's stock is trading near its 52-week low. The acquisition is designed to accelerate Hims & Hers' vision to become a leading global consumer health platform, expanding its presence in the UK, Germany, and Canada, and entering new markets like Australia and Japan. The payment structure includes $240 million in upfront cash, $710 million in deferred payments, and up to $200 million in earnout payments tied to future financial targets. Hims & Hers retains the option to settle the majority of deferred and earnout payments in cash or stock, providing financial flexibility while also introducing potential future dilution. The integration of Eucalyptus, which boasts an annual revenue run-rate of over $450 million with triple-digit year-over-year growth, is expected to significantly enhance Hims & Hers' international capabilities and market leadership.